QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
Subscribe To Our Newsletter & Stay Updated
